The Psychosis Research Program
Led by Sophia Frangou, MD the Psychosis Research Program at the Icahn School of Medicine is dedicated to Affective (primarily Bipolar Disorder) and Non-Affective Psychosis (Schizophrenia and spectrum disorders).
“To promote discovery and accelerate translation of biomedical advances into novel prevention, detection and treatment strategies for psychosis”
Research within the Psychosis Research Program aims to characterize biological pathways in psychosis and understand their relevance for resilience or transition to overt disease expression, progression and treatment response. Key research themes:
- Predictive value of neuroimaging for diagnosis, prognosis and treatment response prediction in psychosis
- Neural correlates of genetic predisposition to bipolar disorder and schizophrenia
- Neural correlates of resilience to expressed genetic vulnerability to bipolar disorder and schizophrenia
- Patient stratification for staging, prognosis and response prediction
- Clinical trials of novel compounds and interventions
The Psychosis Research Program complements efforts within the Division of Psychiatric Genetics to define the genetic architecture of psychosis. In addition the Psychosis Research Program is closely linked to the Translational and Molecular Imaging Institute for neuroimaging research and to the Institute of Genomics and Multiscale Biology for computational and modelling analysis of high-dimensional (genetic, clinical, neuroimaging and psychometric) data.